WO2007120787A3 - Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression - Google Patents
Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression Download PDFInfo
- Publication number
- WO2007120787A3 WO2007120787A3 PCT/US2007/009063 US2007009063W WO2007120787A3 WO 2007120787 A3 WO2007120787 A3 WO 2007120787A3 US 2007009063 W US2007009063 W US 2007009063W WO 2007120787 A3 WO2007120787 A3 WO 2007120787A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- diagnosing
- treating
- liv
- overexpression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009505486A JP2009541208A (en) | 2006-04-13 | 2007-04-12 | How to treat, diagnose, or detect cancer |
EP07755364A EP2012827A2 (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancer |
AU2007238636A AU2007238636A1 (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancer |
MX2008013121A MX2008013121A (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancer. |
CA002650126A CA2650126A1 (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancer |
BRPI0710616-5A BRPI0710616A2 (en) | 2006-04-13 | 2007-04-12 | methods to treat, diagnose or detect cancer |
US12/296,833 US20100196377A1 (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancer |
TNP2008000401A TNSN08401A1 (en) | 2006-04-13 | 2008-10-13 | Methods of treating diagnosing or detecting cancer |
NO20084795A NO20084795L (en) | 2006-04-13 | 2008-11-13 | Procedure for treating, diagnosing or detecting cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79187106P | 2006-04-13 | 2006-04-13 | |
US60/791,871 | 2006-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007120787A2 WO2007120787A2 (en) | 2007-10-25 |
WO2007120787A3 true WO2007120787A3 (en) | 2009-04-30 |
Family
ID=38610188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/009063 WO2007120787A2 (en) | 2006-04-13 | 2007-04-12 | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100196377A1 (en) |
EP (2) | EP2407483A1 (en) |
JP (1) | JP2009541208A (en) |
KR (1) | KR20090010194A (en) |
CN (1) | CN101622273A (en) |
AU (1) | AU2007238636A1 (en) |
BR (1) | BRPI0710616A2 (en) |
CA (1) | CA2650126A1 (en) |
MA (1) | MA30393B1 (en) |
MX (1) | MX2008013121A (en) |
NO (1) | NO20084795L (en) |
TN (1) | TNSN08401A1 (en) |
TW (1) | TW200813231A (en) |
WO (1) | WO2007120787A2 (en) |
ZA (1) | ZA200808669B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
EP2493916B1 (en) * | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
SG10201912646UA (en) | 2010-12-06 | 2020-02-27 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
AU2015222881A1 (en) * | 2014-02-27 | 2016-08-04 | The Procter & Gamble Company | Method for evaluating bioavailable zinc |
KR20160045471A (en) | 2014-10-17 | 2016-04-27 | 대산안전산업 주식회사 | Soundproof panel |
MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
MX2020005640A (en) * | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer. |
CN111289756A (en) * | 2018-12-10 | 2020-06-16 | 北京师范大学 | Urine marker related to lung metastasis and tumor formation of ovarian cancer |
GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
WO2021047507A1 (en) * | 2019-09-09 | 2021-03-18 | 浙江百寿康迪生物医药有限责任公司 | Method for identifying substance capable of affecting aging |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055178A2 (en) * | 2000-01-25 | 2001-08-02 | Genentech, Inc. | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
WO2004066933A2 (en) * | 2003-01-27 | 2004-08-12 | Biogen Idec Ma Inc. | Compositions and methods for treating cancer using igsf9 and liv-1 |
WO2004067564A2 (en) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
WO2004106495A2 (en) * | 2003-05-29 | 2004-12-09 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
WO2005063301A1 (en) * | 2003-12-26 | 2005-07-14 | Toshio Hirano | Emt inducer |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
DK0669836T3 (en) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
CA2132500A1 (en) * | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
KR100942002B1 (en) | 1996-12-03 | 2010-02-12 | 암젠 프레몬트 인코포레이티드 | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
BRPI0410748B8 (en) | 2003-05-20 | 2021-05-25 | Immunogen Inc | maytansinoid compounds, their pharmaceutical compositions, methods of esterification of maytansinoids, as well as methods for their production, and maytansinoid-cell binding agent conjugate |
US7504225B2 (en) * | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
-
2007
- 2007-04-12 AU AU2007238636A patent/AU2007238636A1/en not_active Abandoned
- 2007-04-12 EP EP11171117A patent/EP2407483A1/en not_active Withdrawn
- 2007-04-12 BR BRPI0710616-5A patent/BRPI0710616A2/en not_active IP Right Cessation
- 2007-04-12 EP EP07755364A patent/EP2012827A2/en not_active Withdrawn
- 2007-04-12 CA CA002650126A patent/CA2650126A1/en not_active Abandoned
- 2007-04-12 TW TW096112880A patent/TW200813231A/en unknown
- 2007-04-12 MX MX2008013121A patent/MX2008013121A/en not_active Application Discontinuation
- 2007-04-12 WO PCT/US2007/009063 patent/WO2007120787A2/en active Application Filing
- 2007-04-12 JP JP2009505486A patent/JP2009541208A/en active Pending
- 2007-04-12 CN CN200780021878A patent/CN101622273A/en active Pending
- 2007-04-12 US US12/296,833 patent/US20100196377A1/en not_active Abandoned
- 2007-04-12 KR KR1020087027681A patent/KR20090010194A/en not_active Application Discontinuation
-
2008
- 2008-10-10 ZA ZA200808669A patent/ZA200808669B/en unknown
- 2008-10-13 TN TNP2008000401A patent/TNSN08401A1/en unknown
- 2008-11-03 MA MA31346A patent/MA30393B1/en unknown
- 2008-11-13 NO NO20084795A patent/NO20084795L/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055178A2 (en) * | 2000-01-25 | 2001-08-02 | Genentech, Inc. | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
WO2004066933A2 (en) * | 2003-01-27 | 2004-08-12 | Biogen Idec Ma Inc. | Compositions and methods for treating cancer using igsf9 and liv-1 |
WO2004067564A2 (en) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
WO2004106495A2 (en) * | 2003-05-29 | 2004-12-09 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
WO2005063301A1 (en) * | 2003-12-26 | 2005-07-14 | Toshio Hirano | Emt inducer |
EP1709976A1 (en) * | 2003-12-26 | 2006-10-11 | Toshio Hirano | Emt- inducing agents |
Non-Patent Citations (5)
Title |
---|
CHOWANADISAI W ET AL: "Zinc deficiency is associated with increased brain zinc import and LIV-1 expression and decreased ZnT-1 expression in neonatal rats", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 135, no. 5, May 2005 (2005-05-01), pages 1002 - 1007, XP001207366, ISSN: 0022-3166 * |
KASPER G ET AL: "Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients", INTERNATIONAL JOURNAL OF CANCER, vol. 117, no. 6, December 2005 (2005-12-01), pages 961 - 973, XP002457315, ISSN: 0020-7136 * |
TAYLOR K M ET AL: "Zinc transporter LIV-1: a link between cellular development and cancer progression", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 15, no. 10, December 2004 (2004-12-01), pages 461 - 463, XP004640893, ISSN: 1043-2760 * |
WIMMER U ET AL: "Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione", NUCLEIC ACIDS RESEARCH, vol. 33, no. 18, 2005, pages 5715 - 5727, XP002457325, ISSN: 0305-1048 * |
YAMASHITA S ET AL: "Zinc transporter LIV1 controls epithelial-mesenchymal transition in zebrafish gastrula organizer", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 429, 20 May 2004 (2004-05-20), pages 298 - 302, XP002990283, ISSN: 0028-0836 * |
Also Published As
Publication number | Publication date |
---|---|
TW200813231A (en) | 2008-03-16 |
JP2009541208A (en) | 2009-11-26 |
CA2650126A1 (en) | 2007-10-25 |
ZA200808669B (en) | 2009-10-28 |
MA30393B1 (en) | 2009-05-04 |
CN101622273A (en) | 2010-01-06 |
EP2407483A1 (en) | 2012-01-18 |
BRPI0710616A2 (en) | 2011-08-16 |
TNSN08401A1 (en) | 2010-04-14 |
KR20090010194A (en) | 2009-01-29 |
NO20084795L (en) | 2009-01-13 |
MX2008013121A (en) | 2009-03-25 |
WO2007120787A2 (en) | 2007-10-25 |
EP2012827A2 (en) | 2009-01-14 |
US20100196377A1 (en) | 2010-08-05 |
AU2007238636A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008011519A3 (en) | Amigo-2 inhibitors for treating, diagnosing or detecting cancer | |
WO2008061020A3 (en) | Methods of treating, diagnosing or detecting cancer | |
WO2007120787A3 (en) | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression | |
AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
MX2009012625A (en) | Methods of treating, diagnosing and detecting fgf21-associated disorders. | |
WO2008094708A3 (en) | Activin-actriia antagonists and uses for treating or preventing breast cancer | |
WO2009036427A3 (en) | Prostate cancer biomarkers | |
WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
WO2010009337A3 (en) | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof | |
WO2007061874A3 (en) | Methods and compositions for use in treating cancer | |
WO2006089125A3 (en) | Methods of detecting ovarian cancer | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
WO2009108860A8 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
WO2007134210A8 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
WO2007081720A3 (en) | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
WO2009092108A3 (en) | Biomarkers for the diagnosis and treatment of pancreatic cancer | |
WO2008008923A3 (en) | Compositions and methods for targeting cancer-specific transcription complexes | |
WO2007056049A3 (en) | Molecular profiling of cancer | |
WO2008112192A3 (en) | Epha3 antibodies for the treatment of solid tumors | |
WO2007033167A3 (en) | Compositions and methods for detecting and treating cancer | |
WO2008070472A3 (en) | Use of plasma hsp90 related to malignancy | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
WO2006086772A3 (en) | DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780021878.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07755364 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2650126 Country of ref document: CA Ref document number: 12008502283 Country of ref document: PH Ref document number: MX/A/2008/013121 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194702 Country of ref document: IL Ref document number: 2008101677 Country of ref document: EG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009505486 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007238636 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2007238636 Country of ref document: AU Date of ref document: 20070412 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 572588 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007755364 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027681 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008144658 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12296833 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0710616 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081013 |